Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 ml immediate release
Giovanni Martinotti, Sergio Barlati, Davide Prestía, Claudia Palumbo, Matteo Giordani, Alessandro Cuomo, Andrea Miuli, Carlo Paladini, Mario Amore, Emi Bondi, Antonio Vita, Andrea Fagiolini, Massimo di Giannantonio
Topics & Concepts
AripiprazolePsychomotor agitationDeliriumCoronavirus disease 2019 (COVID-19)Psychomotor learningAnesthesiaPsychomotor disorderMedicinePsychologyPharmacologyPsychiatrySchizophrenia (object-oriented programming)Internal medicineInfectious disease (medical specialty)CognitionDiseaseIntensive Care Unit Cognitive DisordersAnesthesia and Sedative AgentsLong-Term Effects of COVID-19